The Stock That Can't Trade Itself: What MLP Saglik's Liquidity Provider Reveals

MLP Saglik, Turkey's largest private hospital operator, has grown revenue 6% year-over-year, expanded EBITDA margins above 29%, and runs 34 hospitals across 13 cities. The business is working.

The stock is not.

On Thursday, September 11, MLP Saglik (ticker: MPARK, traded on Borsa Istanbul) disclosed that an investment firm called OYA had been buying and selling its shares as a designated liquidity provider. The announcement was routine, transparent, and nearly meaningless to anyone who doesn't understand what it reveals about the structure of this investment.

This is the second time this year MLP Saglik has needed the same arrangement. In late July, OYA ran an identical liquidity-providing program for the same stock. The company reports these trades publicly. That transparency is the first clue: the normal market is not providing normal liquidity.

What a liquidity provider actually does

A liquidity provider is an authorized financial intermediary that sits in the order book and continuously places both buy and sell orders at quoted prices. When natural buyer-seller matching is too thin, the provider steps in to ensure trades can execute, spreads stay tight, and the stock doesn't gap around isolated orders.

Liquidity providers earn the bid-ask spread — the difference between what they offer to buy and what they ask to sell. They are not taking a directional view on the company. They are providing an infrastructure service: keeping the market from freezing.

This arrangement is standard on Borsa Istanbul for companies with concentrated ownership and a narrow free float. It is a regulatory-allowed tool, not a sign of fraud or imminent trouble. It also tells you exactly what the underlying problem is: there are not enough independent shareholders willing to trade freely.

The ownership trap

The top 25 shareholders of MLP Saglik collectively own approximately 78% of the company. The largest single holder, Sancak Insaat ve Nakliyat, sits at 16.7%. That leaves a free float of roughly 22% — the portion actually available to trade on the open market. For a company with a market capitalization near 83 billion Turkish lira, that float is narrow enough that a single institutional-sized order can move the price meaningfully.

This structure is not accidental. In September 2025, a major shareholder — Lightyear Healthcare BV, advised by Turkven — sold a block of B-class shares representing 15% of the company's capital in one of the largest block trades on Borsa Istanbul in five years. The transaction drew more than $600 million in investor demand, with international funds absorbing the majority. At the same time, Lightyear's 25% stake in unlisted A-class shares was transferred to Muharrem Usta, the company's founder and chairman.

The founder is consolidating control of the private voting shares while the publicly traded portion changes hands through institutional block trades. The result is a stock where the most committed long-term capital is locked in unlisted shares, the listed portion is owned by a concentrated group, and the remaining float is too thin to sustain organic two-way trading without a designated market maker.

What the financials show

The company's operations are genuinely strong, which makes the liquidity problem more instructive. For fiscal year 2025, MLP Saglik reported revenue of 55.1 billion Turkish lira with EBITDA of 15.3 billion and a 27.8% margin. In the first quarter of 2026, revenue grew 6% to 16.25 billion lira, EBITDA rose 25% year-over-year to 4.81 billion, and the EBITDA margin expanded to 29.6%. The growth is supported by rising private medical insurance penetration in Turkey and a recovery in international patient flows.

The stock has performed well in lira terms: up roughly 16% year-to-date as of early September. But the average daily trading volume hovers around 735,000 shares. At the current price near 427 lira per share, that is approximately 313 million lira of daily turnover — less than 0.4% of market capitalization. For comparison, widely traded U.S. large-cap stocks typically see turnover exceeding 1% of market cap on ordinary days.

The numbers tell a coherent story: a high-quality business whose shares trade in a market that is structurally thin. The liquidity provider bridges that gap. When the provider is active, the stock behaves normally. When it is not, the price reacts sharply to whatever order flow happens to arrive.

Why this matters for the investor

You cannot invest in a stock the way you invest in a business if you cannot trade the stock normally. The liquidity constraint introduces three practical risks that have nothing to do with the hospital business:

Exit timing. If you need to sell a meaningful position, you cannot simply click "sell" and expect an orderly execution. A large order in a thin float moves the price against you — and there may not be enough natural buyers to absorb it. The liquidity provider mitigates this but does not eliminate it; they are an intermediary, not a guaranteed buyer at any price.

Price dislocation. Thin floats amplify the impact of news, currency swings, and sector sentiment. A Turkish lira depreciation, a regulatory announcement in Ankara, or a sell signal from a concentrated holder can push the stock far from what the underlying business justifies — and the move can persist because there are not enough independent traders to counter it.

Asymmetric information. The concentrated shareholders and the founder know the business intimately. Foreign institutional investors in the block trades have access to diligence and roadshows. Retail investors on the open market have the order book, the periodic disclosures, and whatever the liquidity provider decides to quote. The information and access gap is real, even if the company discloses regularly.

The amplifier and the firewall

The amplifier here is the concentrated ownership combined with Turkey's currency and regulatory environment. The lira remains volatile. The Turkish capital markets have experienced episodes of sudden repricing. A company with 78% of shares held by a group of 25 insiders, operating in a currency that swings on monetary policy, creates a perfect setup where the float can detach from fundamentals.

The firewall is the company's actual cash generation and the regulatory framework that requires transparency. MLP Saglik generates substantial free cash flow from its hospital operations. The liquidity trades are disclosed publicly, including volumes and prices. The Turkish Capital Markets Board oversees these arrangements. Neither the company nor its provider can quietly manipulate the price without leaving a trail.

The pattern that matters

The important signal is not that MLP Saglik uses a liquidity provider once. It is that they use one repeatedly — July and September, just two months apart. This is not a one-time stabilization after a listing or a block trade. This is the normal state of the market for this stock.

That tells you the structural condition is not resolving. The concentration is not diluting. The natural trading base is not growing to a point where the intermediary is no longer needed. Unless the free float expands through a new issuance, a secondary block trade that distributes shares broadly, or a sustained inflow of independent buyers, the liquidity dependency will continue.

What this is not

This article is not saying MLP Saglik is a bad investment. The hospital business is growing, margins are expanding, and the management has executed across currency and regulatory cycles. The liquidity issue does not make the fundamentals worse.

It is also not saying the stock is impossible to trade. Small positions can enter and exit without moving the market. The problem scales with size and timing.

The point is narrower and more important: there is a layer of risk between you and the business that has nothing to do with patients, doctors, or hospital margins. Understanding that layer changes how you size the position, how you think about exit, and what you monitor.

Where the chain stops

The liquidity risk fades if the free float meaningfully expands, if sustained institutional ownership creates a natural two-way market, or if the Turkish equity market deepens enough that a hospital operator's stock no longer needs a dedicated intermediary to function.

It persists if ownership remains concentrated, block trades continue to move institutional-sized positions through private negotiations rather than open-market trading, and the company continues its cycle of periodic liquidity disclosures.

For anyone considering MPARK as an investment, the question is not whether the hospital business is worth owning. The question is whether you can own it in a market where the price is partly set by an intermediary whose job is to keep things from breaking — and whether that distinction matters to the size of position you are comfortable holding.